Skip to main content
All Posts By

cece

Science Direct
Immunotherapy in non-small cell lung cancer harbouring driver mutations ResearchTreatments

Immunotherapy in non-small cell lung cancer harbouring driver mutations

*May 2021* The advent of molecular targeted therapies and the more recent introduction of immune checkpoint inhibitors (ICIs) have altered and improved the therapeutic landscape of non-small cell lung cancer (NSCLC). ICIs confer a durable response in a subset of patients; however, their therapeutic role in oncogene-driven NSCLC remains unclear,…
cece
June 19, 2021
OncLive
Osimertinib Continues to Enhance Outcomes in EGFR+ NSCLC ResearchTreatments

Osimertinib Continues to Enhance Outcomes in EGFR+ NSCLC

*March 2021* Osimertinib (Tagrisso) has demonstrated significant benefit in the frontline metastatic and adjuvant settings in patients with stage IV and stage IB-IIIA EGFR-mutant non–small cell lung cancer (NSCLC), respectively, explained Lara A. Kujtan, MD, but added that the ongoing phase 3 FLAURA2 (NCT04035486), LAURA (NCT03521154), and NeoADAURA (NCT04351555) trials could…
cece
June 19, 2021
Exploring EGFR Mutations in Lung Cancer: Key Diagnostic & Management Strategies ResearchTreatments

Exploring EGFR Mutations in Lung Cancer: Key Diagnostic & Management Strategies

*April 2021* Lung cancer expert Dr. Pasi Janne, a professor of medicine at Harvard Medical School and a translational thoracic medical oncologist at the Dana-Farber Cancer Institute, speaks about EGFR treatments including post-progression following osimertinib. This is a very informative podcast and easy to understand. Listen to the podcast or read the…
cece
June 19, 2021
EGFR Resisters logo
EGFR Resisters Self-Funded Research Projects for 2021 ResearchTreatments

EGFR Resisters Self-Funded Research Projects for 2021

*March 2021* Want to know more details about our two self-funded EGFR Resisters research projects in partnership with LUNGevity? 1. TARGETING DRUG TOLERANT STATES + DNA DAMAGE TO BLOCK OSIMERTINIB RESISTANCE, conducted by Christine Lovly, MD, PhD Despite high tumor response rates, patients treated with EGFR targeted therapies, such as osimertinib, inevitably…
cece
June 19, 2021
EGFR Resisters logo
EGFR Resisters and LUNGevity Foundation Partner on Lung Cancer Research Award FundingPartnersResearchTreatments

EGFR Resisters and LUNGevity Foundation Partner on Lung Cancer Research Award

*February 2021* WASHINGTON, Feb. 19, 2021 /PRNewswire/ -- Patient group EGFR Resisters and LUNGevity Foundation today announced the 2021 recipients of the first EGFR Resisters/LUNGevity Lung Cancer Research Award. This award program, driven by EGFR Resisters—a grassroots patient-led group that has 2,500+ patients and caregivers from 75+ countries—supports critical research that seeks to…
cece
June 19, 2021